Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Cynosure Inc (NASDAQ: CYNO) acted responsibly on behalf of investors’ profitability in the planned $1.65 billion sale to Hologic Inc (NASDAQ: HOLX).

On February 14, 2017, Cynosure Inc (NASDAQ: CYNO) and Hologic Inc (NASDAQ: HOLX) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Hologic will offer Cynosure shareholders $66 per share in cash for all outstanding shares.    

Based in Westford, Massachusetts, and founded in 1991 Cynosure Inc develops, manufactures, and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners.

The investigation focuses on whether NASDAQ: CYNO investors received the highest price and whether the directors of Cynosure Inc acted in the best interest of Cynosure Inc company and its shareholders.  

If you purchased Cynosure Inc (NASDAQ: CYNO) prior to February 14, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185